Safety and tolerability of long-term administration of dilaudid SR [slow release] (hydromorphone HCI) in cancer pain
Phase of Trial: Phase III
Latest Information Update: 14 Jul 2009
At a glance
- Drugs Hydromorphone (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors ALZA Corporation
- 14 Jul 2009 Actual patient number (68) added as reported by ClinicalTrials.gov.
- 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jul 2009 Actual end date Apr 2002 added as reported by ClinicalTrials.gov.